FHTX — Foghorn Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $289.39m
- $130.50m
- $30.91m
Annual cashflow statement for Foghorn Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -101 | -109 | -98.4 | -86.6 | -74.3 |
| Depreciation | |||||
| Non-Cash Items | 14.4 | 17.6 | 18.7 | 15.4 | 17 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 33.4 | 282 | -41.9 | -32.3 | -32.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -50.3 | 194 | -118 | -100 | -86.1 |
| Capital Expenditures | -3.31 | -1.21 | -1.22 | -0.906 | -0.05 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 39.5 | -243 | 146 | -29 | 112 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 36.2 | -244 | 144 | -29.9 | 112 |
| Financing Cash Flow Items | 42.2 | 0 | — | -0.585 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 22.4 | 1.76 | 1.78 | 105 | 1.02 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.34 | -48.9 | 28.1 | -24.9 | 27 |